Department of Medicine, VA Connecticut Healthcare System, West Haven.
Department of Internal Medicine, Yale University School of Medicine, New Haven.
AIDS. 2021 Nov 15;35(14):2355-2365. doi: 10.1097/QAD.0000000000003019.
People with HIV (PWH) with access to antiretroviral therapy (ART) experience excess morbidity and mortality compared with uninfected patients, particularly those with persistent viremia and without CD4+ cell recovery. We compared outcomes for medical intensive care unit (MICU) survivors with unsuppressed (>500 copies/ml) and suppressed (≤500 copies/ml) HIV-1 RNA and HIV-uninfected survivors, adjusting for CD4+ cell count.
We studied 4537 PWH [unsuppressed = 38%; suppressed = 62%; 72% Veterans Affairs-based (VA) and 10 531 (64% VA) uninfected Veterans who survived MICU admission after entering the Veterans Aging Cohort Study (VACS) between fiscal years 2001 and 2015.
Primary outcomes were all-cause 30-day and 6-month readmission and mortality, adjusted for demographics, CD4+ cell category (≥350 (reference); 200-349; 50-199; <50), comorbidity and prior healthcare utilization using proportional hazards models. We also adjusted for severity of illness using discharge VACS Index (VI) 2.0 among VA-based survivors.
In adjusted models, CD4+ categories <350 cells/μl were associated with increased risk for both outcomes up to 6 months, and risk increased with lower CD4+ categories (e.g. 6-month mortality CD4+ 200-349 hazard ratio [HR] = 1.35 [1.12-1.63]; CD4+ <50 HR = 2.14 [1.72-2.66]); unsuppressed status was not associated with outcomes. After adjusting for VI in models stratified by HIV, VI quintiles were strongly associated with both outcomes at both time points.
PWH who survive MICU admissions are at increased risk for worse outcomes compared with uninfected, especially those without CD4+ cell recovery. Severity of illness at discharge is the strongest predictor for outcomes regardless of HIV status. Strategies including intensive case management for HIV-specific and general organ dysfunction may improve outcomes for MICU survivors.
与未感染的患者相比,接受抗逆转录病毒治疗(ART)的艾滋病毒(HIV)感染者(PWH)的发病率和死亡率更高,尤其是那些持续存在病毒血症且 CD4+细胞未恢复的患者。我们比较了未抑制(>500 拷贝/ml)和抑制(≤500 拷贝/ml)HIV-1 RNA 的重症监护病房(MICU)幸存者以及 HIV 未感染者幸存者的结局,同时调整了 CD4+细胞计数。
我们研究了 4537 名 PWH [未抑制组为 38%;抑制组为 62%;72%基于退伍军人事务部(VA),10531 名(64%基于 VA)HIV 未感染者幸存者在 2001 财政年度至 2015 财政年度期间进入退伍军人老龄化队列研究(VACS)后成功入住 MICU]。
主要结局是全因 30 天和 6 个月的再入院和死亡率,调整了人口统计学、CD4+细胞类别(≥350(参考);200-349;50-199;<50)、合并症和使用比例风险模型的既往医疗保健使用情况。我们还通过退伍军人事务部幸存者的出院 VACS 指数(VI)2.0 调整了疾病严重程度。
在调整后的模型中,<350 个细胞/μl 的 CD4+细胞类别与长达 6 个月的两种结局都有较高的风险相关,且风险随 CD4+细胞类别的降低而增加(例如,6 个月死亡率 CD4+200-349 危险比 [HR] = 1.35 [1.12-1.63];CD4+<50 HR = 2.14 [1.72-2.66]);未抑制状态与结局无关。在按 HIV 分层的模型中调整 VI 后,在两个时间点,VI 五分位数与两种结局均密切相关。
与 HIV 未感染者相比,成功入住 MICU 的 PWH 的预后更差,尤其是那些 CD4+细胞未恢复的患者。出院时的疾病严重程度是无论 HIV 状态如何,预测结局的最强指标。包括针对 HIV 特异性和一般器官功能障碍的强化病例管理在内的策略,可能会改善 MICU 幸存者的结局。